Sodium-glucose cotransporter 2 (SGLT2) inhibitors are the insulin-independent, glucose-dependent antihyperglycemic agents and demonstrate some potential in the treatment of type 1 diabetes 12–15. The gene discussed is SLC5A2; the disease is type 1 diabetes mellitus.